Business Context and Reporting Period
Company: Viemed Healthcare, Inc.
Filing Type: Form 8-K (Current Report)
Date: November 29, 2022
Event: Entry into a Material Definitive Agreement (Senior Credit Facilities) and termination of a previous credit facility.
Key Financial Metrics and Debt Structure
This filing details a new credit facility rather than reporting period-end financial performance metrics (revenue, profit, cash flow). Key debt terms include:
- Total Facility Size: Up to $60 million aggregate principal.
- Revolving Credit Facility: Up to $30 million (5-year term). Includes a $5 million sublimit for letters of credit and a $5 million sublimit for swing line loans.
- Delayed Draw Term Loan (DD Term Loan): $30 million. Available for drawdowns in minimum amounts of $5 million for 18 months post-closing.
- Interest Rates: Term SOFR + 2.625% to 3.375% OR Base Rate + 1.625% to 2.375%.
- Amortization (DD Term Loan): 5.0% per annum (through June 30, 2024); 7.5% per annum (Sept 30, 2024 – June 30, 2026); 10.0% per annum (thereafter).
- Collateral: First-priority security interest in all present and future shares of subsidiaries, personal property, assets, and proceeds.
Material Changes Versus Prior Period
- Refinancing: The Company repaid in full and terminated its previous "Commercial Business Loan Agreement" dated February 21, 2018.
- Use of Proceeds: Revolving facility proceeds will refinance existing indebtedness, fund working capital, capital expenditures, and permitted acquisitions. DD Term Loan proceeds are designated for permitted acquisitions.
- Capacity Increase: The agreement allows for potential increases in the Revolving Facility and additional Term Loans up to an aggregate of $30 million, subject to lender approval.
Covenants, Risks, and Management Commentary
Financial Covenants:
- Consolidated Total Leverage Ratio: Maximum 2.75:1.0 (through Dec 31, 2024) and 2.50:1.0 (thereafter). A temporary increase to 3.00:1.0 is permitted for four quarters following a Material Acquisition.
- Consolidated Fixed Charge Coverage Ratio: Minimum 1.25:1.0.
Mandatory Prepayments:
- 50% of Consolidated Excess Cash Flow (reduced to 25% or 0% based on leverage ratios).
- 100% of net cash proceeds from asset sales, involuntary dispositions, or unauthorized debt issuances.
Equity Cure: The Company may make capital contributions to the Borrower to cure financial covenant defaults, which will then be applied to reduce Term Loans.
Risks: The agreement restricts the ability to incur additional indebtedness, grant liens, make investments, engage in mergers, or pay dividends without meeting specific exceptions.
Investor Verification Checklist
- Verify the exact amount drawn from the $60 million facility on the closing date versus the total commitment.
- Confirm the current Consolidated Total Leverage Ratio and Fixed Charge Coverage Ratio to assess immediate covenant compliance.
- Review the definition of "Permitted Acquisitions" to understand the scope of future M&A activity funded by the DD Term Loan.
- Monitor the "Consolidated Excess Cash Flow" calculation to estimate mandatory prepayment obligations starting fiscal year 2023.
- Check for any subsequent filings regarding the utilization of the 18-month draw period for the Delayed Draw Term Loan.